Cash, cash equivalents and marketable securities were $137.2M as of December 31, 2023, which is projected to fund operations into the second half of 2025. “We are very pleased with the foundational progress we made in 2023. Building on this, we expect 2024 to be an exciting year in which we demonstrate the Vor Bio approach to be instrumental in reducing the disease burden of AML, a devastating cancer where we desperately need effective treatment options,” said Robert Ang, Vor Bio’s president and CEO.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VOR:
- Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
- VOR Upcoming Earnings Report: What to Expect?
- Vor Bio treatment of acute myeloid leukemia granted FDA orphan designation
- Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Vor Bio to Participate in Upcoming Investor Conferences
